PTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial Results

SOUTH PLAINFIELD, N.J., Oct. 19, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. today announced that the Company will host a webcast conference call to report its third quarter financial results and provide an update on the company's business and outlook on Thursday, November 2, 2017 at 4:30 p.m. (ET) after the closing of the market.

The call can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 2261347. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at www.ptcbio.com. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for two weeks.

About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines using our expertise in RNA biology. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. PTC has discovered all of its compounds currently under development using its proprietary technologies. Since its founding nearly 20 years ago, PTC's mission has focused on developing treatments to fundamentally change the lives of patients living with rare genetic disorders. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey. For more information on the company, please visit our website www.ptcbio.com.

    For More Information Please Contact:



    Media:                               Investors:

    Jane Baj                             Emily Hill

    +1 (908) 912-9167                                     +1 (908) 912-9327

    jbaj@ptcbio.com                      ehill@ptcbio.com

View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-to-host-conference-call-to-discuss-third-quarter-financial-results-300539550.html

SOURCE PTC Therapeutics, Inc.